Journal of Pharmaceutical and Biomedical Analysis · 2023 · 17 citations · 22 references
MedicineBiochemistryNeurologyAgingDementiaNeurochemistryAge-related Physiological ChangesBiomarkers Of NeurodegenerationCognitive AgingCognitive ImpairmentDementia BiomarkersDementia DiagnosisAge-related Metabolic DeclineDisease-specific BiomarkersMetabolic BiomarkersMetabolic Changes In AgingMetabolic Changes With AgingMetabolic Disease BiomarkersNuclear Magnetic Resonance SpectroscopyUnknown Metabolite Characterization
BACKGROUND: Blood biomarkers can improve the ability to diagnose dementia, providing new information to better understand the pathophysiology and causes of the disease. Some studies with patients have already shown changes in metabolic profiles among patients with pathological cognitive decline or Alzheimer's disease, when compared to individuals with normal cognition. METHODS: To search for new metabolic biomarkers of dementia, we analyzed serum levels of several metabolites, measured by nuclear magnetic resonance spectroscopy, in elderly individuals, a group with normal cognitive decline (control), and three other groups with cognitive decline. pathological (low, moderate, and severe). RESULTS: Decreased plasma levels of tyrosine, glutamate, valine, leucine, and isoleucine are associated with worsening of pathological cognitive decline. However, the area under analysis of receptor operating characteristics suggests that tyrosine and glutamate have low specificity and sensitivity. Valine, leucine, and isoleucine are influenced by blood glucose or diabetes, but these conditions do not seem to be of great influence in the differences observed. Isobutyrate, histidine, acetone and unknown-1 metabolite also decrease their plasma levels with increasing CD. Isobutyrate ad histidine could have neuroprotective and antioxidant actions, respectively. To elucidate the role of decreased unknown metabolite-1 as a CD biomarker, it will be necessary to previously investigate its identity. To define and elucidate the role of acetone in pathological CD, additional laboratory and clinical studies must be performed. All these metabolites together may constitute a set of biomarkers with capability to identify pathological CD or dementia. SIGNIFICANCE AND NOVELTY: Decrease of glutamate, tyrosine, valine, leucine, isoleucine, histidine, isobutyrate, acetone and unknown-1 metabolite together are a set of biomarkers able to identify pathological CD or dementia. Histidine, isobutyrate, acetone and unknown-1 metabolite are more specific biomarkers of CD.
22
Nikolaos Psychogios, David Hau, Jun Peng et al. · PLoS ONE · 2011 · 1.7K citations · Full text
Life Sciences, Biochemistry, Mass Spectrometric Analysis +16
Metabolic network failures in Alzheimer's disease: A biochemical road map
Jon B. Toledo, Matthias Arnold, Gabi Kastenmüller et al. · Alzheimer s & Dementia · 2017 · 496 citations · Full text